biology-technology-1/ucb-and-crohns-disease-working-group-award--24175-000-in-research-grants-to-gastroenterology-fellows-12383-2/;/a><br

Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3 BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3 Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4 Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2 Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2 Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3

[0] BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year [0] Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe [0] Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results [0] Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India

Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4 Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5 Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2 Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3 Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4 Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5 Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2 Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3 NYU physicists find way to explore microscopic systems through holographic video 13103 1 NYU physicists find way to explore microscopic systems through holographic video 13103 2 NYU physicists find way to explore microscopic systems through holographic video 13103 3 May Institute National Autism Center and Automoblox Launch Cars for Classrooms Summer Charitable Campaign to Benefit Children with Autism 52162 1 May Institute National Autism Center and Automoblox Launch Cars for Classrooms Summer Charitable Campaign to Benefit Children with Autism 52162 2 May Institute National Autism Center and Automoblox Launch Cars for Classrooms Summer Charitable Campaign to Benefit Children with Autism 52162 3 May Institute National Autism Center and Automoblox Launch Cars for Classrooms Summer Charitable Campaign to Benefit Children with Autism 52162 4 Insulet Corporation to Report Second Quarter 2009 Financial Results on Tuesday August 4 2009 52157 1 Insulet Corporation to Report Second Quarter 2009 Financial Results on Tuesday August 4 2009 52157 2

[0] Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease [0] Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study [0] Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing